<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970930</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0481</org_study_id>
    <nct_id>NCT01970930</nct_id>
  </id_info>
  <brief_title>Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV &amp; ET) Patients</brief_title>
  <official_title>Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to isolate and characterize stem cells of patients with
      Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are
      not working the way they should be and why they seem to be sensitive to regulatory factors
      in the blood, such as clotting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it
      affects MPN stem cell function.

      Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN
      HSC/HPC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Stem cell function</measure>
    <time_frame>at one time study visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD34+ cells assays</measure>
    <time_frame>at one time study visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>PV or ET</arm_group_label>
    <description>subject who has polycythemia vera or essential thrombocythemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood specimen</intervention_name>
    <description>4 green top tube 40 cc of blood draw</description>
    <arm_group_label>PV or ET</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CD34+ cells isolated from the peripheral blood Splenic CD34+ cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have polycythemia vera or essential thrombocythemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  polycythemia vera or essential thrombocythemia

          -  agree to give blood for study

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Kleczko, MPA</last_name>
    <phone>212-241-0573</phone>
    <email>jill.kleczko@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald Hoffman, MD</last_name>
    <phone>212-241-2296</phone>
    <email>ronald.hoffman@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronald Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>August 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue banking</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
